Connection
Wells Messersmith to Response Evaluation Criteria in Solid Tumors
This is a "connection" page, showing publications Wells Messersmith has written about Response Evaluation Criteria in Solid Tumors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.036 |
|
|
|
-
Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer. 2017 Oct 01; 123(19):3843-3854.
Score: 0.036